{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:37Z","timestamp":1794047497750,"version":"4.8.0"},"reference-count":33,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"8","license":[{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Patients with chronic lymphocytic leukemia (CLL) have an impaired response to vaccination, which calls for improved vaccination strategies. This study aimed to evaluate antibody persistence 5 years after pneumococcal vaccination and response to revaccination. Seventy-four CLL patients and 31 controls, all primary immunized with 13-valent conjugated pneumococcal vaccine (PCV13) or 23-valent polysaccharide vaccine (PPSV23), were included. Antibody persistence was assessed, followed by revaccination with PCV13 and a second revaccination with PCV13 or PPSV23. Serological protection, defined as a serum serotype-specific IgG concentration \u22650.35 \u03bcg\/mL for \u226570% of shared serotypes, did not differ significantly in CLL patients primary immunized with PCV13 or PPSV23 (relative risk ratio [RR]=2.7, 95% confidence interval [95% CI]: 0.5-13.1), but was lower in patients than in controls (10% vs. 32%; RR=0.3; 95% CI: 0.1-0.7). Following revaccination with PCV13, serological response, defined as a \u22652-fold increase for \u226570% of shared serotypes, was 24% in patients primary immunized with PCV13 compared to 12% in those primary immunized with PPSV23 (RR=2.0; 95% CI: 0.6-6.9). A second revaccination with PCV13 significantly improved serological response while PPSV23 did not further improve immunity. Our findings suggest that repeated doses of a T-cell-dependent pneumococcal vaccine improve protection in CLL patients. The study is registered at www.clinicaltrials.gov (NCT05316831).<\/jats:p>","DOI":"10.3324\/haematol.2024.286942","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T03:39:21Z","timestamp":1741232361000},"page":"1774-1785","source":"Crossref","is-referenced-by-count":1,"title":["Revaccination with pneumococcal conjugate vaccine five years after primary immunization improves immunity in patients with chronic lymphocytic leukemia"],"prefix":"10.3324","volume":"110","author":[{"given":"Magdalena","family":"K\u00e4ttstr\u00f6m","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertil","family":"Uggla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Virta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merit","family":"Melin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Ekstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Magnuson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per-Ola","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ylva","family":"Hammarlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Lockmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingmar","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Svensson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Tolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Kimby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torbj\u00f6rn","family":"Nor\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Athlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"key":"77383","doi-asserted-by":"crossref","unstructured":"Francis ER, Vu J, Perez CO, Sun C. Vaccinations in patients with chronic lymphocytic leukemia. Semin Hematol. 2024; 61(2):131-138.","DOI":"10.1053\/j.seminhematol.2024.01.003"},{"key":"77384","doi-asserted-by":"crossref","unstructured":"Forconi F, Moss P. Perturbation of the normal immune system in patients with CLL. Blood. 2015; 126(5):573-581.","DOI":"10.1182\/blood-2015-03-567388"},{"key":"77385","doi-asserted-by":"crossref","unstructured":"Parikh SA, Leis JF, Chaffee KG. Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: natural history, clinical correlates, and outcomes. Cancer. 2015; 121(17):2883-2891.","DOI":"10.1002\/cncr.29438"},{"key":"77386","doi-asserted-by":"crossref","unstructured":"Grywalska E, Zaborek M, Lyczba J. Chronic lymphocytic leukemia-induced humoral immunosuppression: a systematic review. Cells. 2020; 9(11):2398.","DOI":"10.3390\/cells9112398"},{"key":"77387","doi-asserted-by":"crossref","unstructured":"Palma M, Mulder TA, Osterborg A. BTK inhibitors in chronic lymphocytic leukemia: biological activity and immune effects. Front Immunol. 2021; 12:686768.","DOI":"10.3389\/fimmu.2021.686768"},{"key":"77388","doi-asserted-by":"crossref","unstructured":"Mauro FR, Giannarelli D, Galluzzo CM. Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL). Leukemia. 2021; 35(3):737-746.","DOI":"10.1038\/s41375-020-0884-z"},{"key":"77389","doi-asserted-by":"crossref","unstructured":"Vijenthira A, Gong I, Betschel SD, Cheung M, Hicks LK. Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients. Blood Adv. 2021; 5(12):2624-2643.","DOI":"10.1182\/bloodadvances.2021004629"},{"key":"77390","doi-asserted-by":"crossref","unstructured":"Andrick B, Alwhaibi A, DeRemer DL. Lack of adequate pneumococcal vaccination response in chronic lymphocytic leukaemia patients receiving ibrutinib. Br J Haematol. 2018; 182(5):712-714.","DOI":"10.1111\/bjh.14855"},{"key":"77391","doi-asserted-by":"crossref","unstructured":"Andersen MA, Niemann CU, Rostgaard K. Differences and temporal changes in risk of invasive pneumococcal disease in adults with hematological malignancies: results from a nationwide 16-year cohort study. Clin Infect Dis. 2021; 72(3):463-471.","DOI":"10.1093\/cid\/ciaa090"},{"key":"77392","doi-asserted-by":"crossref","unstructured":"Garcia Garrido HM, Knol MJ, Heijmans J. Invasive pneumococcal disease among adults with hematological and solid organ malignancies: a population-based cohort study. Int J Infect Dis. 2021; 106:237-245.","DOI":"10.1016\/j.ijid.2021.03.072"},{"key":"77393","doi-asserted-by":"crossref","unstructured":"Morrison VA. Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches. Best Pract Res Clin Haematol. 2010; 23(1):145-153.","DOI":"10.1016\/j.beha.2009.12.004"},{"key":"77394","doi-asserted-by":"crossref","unstructured":"Sinisalo M, Vilpo J, Itala M, Vakevainen M, Taurio J, Aittoniemi J. Antibody response to 7-valent conjugated pneumococcal vaccine in patients with chronic lymphocytic leukaemia. Vaccine. 2007; 26(1):82-87.","DOI":"10.1016\/j.vaccine.2007.10.053"},{"key":"77395","doi-asserted-by":"crossref","unstructured":"Svensson T, Kattstrom M, Hammarlund Y. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group. Vaccine. 2018; 36(25):3701-3707.","DOI":"10.1016\/j.vaccine.2018.05.012"},{"key":"77396","doi-asserted-by":"crossref","unstructured":"Pasiarski M, Rolinski J, Grywalska E. Antibody and plasmablast response to 13-valent pneumococcal conjugate vaccine in chronic lymphocytic leukemia patients--preliminary report. PLoS One. 2014; 9(12):e114966.","DOI":"10.1371\/journal.pone.0114966"},{"key":"77397","doi-asserted-by":"crossref","unstructured":"Lindstrom V, Aittoniemi J, Salmenniemi U, Kayhty H, Huhtala H, Sinisalo M. Antibody response to the 23-valent pneumococcal polysaccharide vaccine after conjugate vaccine in patients with chronic lymphocytic leukemia. Hum Vaccin Immunother. 2019; 15(12):2910-2913.","DOI":"10.1080\/21645515.2019.1627160"},{"key":"77398","doi-asserted-by":"crossref","unstructured":"Haggenburg S, Garcia Garrido HM, Kant IMJ. Immunogenicity of the 13-valent pneumococcal conjugated vaccine followed by the 23-valent polysaccharide vaccine in chronic lymphocytic leukemia. Vaccines (Basel). 2023; 11(7):1201.","DOI":"10.3390\/vaccines11071201"},{"key":"77399","doi-asserted-by":"crossref","unstructured":"Mikulska M, Cesaro S, de Lavallade H. Vaccination of patients with haematological malignancies who did not have transplantations: guidelines from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019; 19(6):e188-e199.","DOI":"10.1016\/S1473-3099(18)30601-7"},{"key":"77400","doi-asserted-by":"crossref","unstructured":"Cannon K, Elder C, Young M. A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults \u226565 years of age with different prior pneumococcal vaccination. Vaccine. 2021; 39(51):7494-7502.","DOI":"10.1016\/j.vaccine.2021.10.032"},{"key":"77401","doi-asserted-by":"crossref","unstructured":"Cordonnier C, Ljungman P, Juergens C. Immunogenicity, safety, and tolerability of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipients of allogeneic hematopoietic stem cell transplant aged \u22652 years: an open-label study. Clin Infect Dis. 2015; 61(3):313-323.","DOI":"10.1093\/cid\/civ287"},{"key":"77402","doi-asserted-by":"crossref","unstructured":"Timby N, Hernell O, Vaarala O, Melin M, Lonnerdal B, Domellof M. Infections in infants fed formula supplemented with bovine milk fat globule membranes. J Pediatr Gastroenterol Nutr. 2015; 60(3):384-389.","DOI":"10.1097\/MPG.0000000000000624"},{"key":"77403","doi-asserted-by":"crossref","unstructured":"Orange JS, Ballow M, Stiehm ER. Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2012; 130(3 Suppl):S1-24.","DOI":"10.1016\/j.jaci.2012.07.002"},{"key":"77404","doi-asserted-by":"crossref","unstructured":"Lindstrom V, Aittoniemi J, Salmenniemi U. Antibody persistence after pneumococcal conjugate vaccination in patients with chronic lymphocytic leukemia. Hum Vaccin Immunother. 2018; 14(6):1471-1474.","DOI":"10.1080\/21645515.2018.1436424"},{"key":"77405","doi-asserted-by":"crossref","unstructured":"Frenck RW Jr, Fiquet A, Gurtman A. Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older. Vaccine. 2016; 34(30):3454-3462.","DOI":"10.1016\/j.vaccine.2016.04.093"},{"key":"77406","doi-asserted-by":"crossref","unstructured":"Jackson LA, Gurtman A, Rice K. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. Vaccine. 2013; 31(35):3585-3593.","DOI":"10.1016\/j.vaccine.2013.05.010"},{"key":"77407","doi-asserted-by":"crossref","unstructured":"Kattstrom M, Uggla B, Tina E, Kimby E, Noren T, Athlin S. Improved plasmablast response after repeated pneumococcal revaccinations following primary immunization with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia. Vaccine. 2023; 41(19):3128-3136.","DOI":"10.1016\/j.vaccine.2023.04.016"},{"key":"77408","doi-asserted-by":"crossref","unstructured":"Wodi AP, Murthy N, McNally VV, Daley MF, Cineas S. Advisory Committee on Immunization Practices recommended immunization schedule for children and adolescents aged 18 years or younger - United States, 2024. MMWR Morb Mortal Wkly Rep. 2024; 73(1):6-10.","DOI":"10.15585\/mmwr.mm7301a2"},{"key":"77409","doi-asserted-by":"crossref","unstructured":"Cordonnier C, Einarsdottir S, Cesaro S. Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019; 19(6):e200-e212.","DOI":"10.1016\/S1473-3099(18)30600-5"},{"key":"77410","doi-asserted-by":"crossref","unstructured":"Cordonnier C, Labopin M, Robin C. Long-term persistence of the immune response to antipneumococcal vaccines after allo-SCT: 10-year follow-up of the EBMT-IDWP01 trial. Bone Marrow Transplant. 2015; 50(7):978-983.","DOI":"10.1038\/bmt.2015.42"},{"key":"77411","doi-asserted-by":"crossref","unstructured":"Chichili GR, Smulders R, Santos V. Phase 1\/2 study of a novel 24-valent pneumococcal vaccine in healthy adults aged 18 to 64 years and in older adults aged 65 to 85 years. Vaccine. 2022; 40(31):4190-4198.","DOI":"10.1016\/j.vaccine.2022.05.079"},{"key":"77412","unstructured":"Recommendations for the production and control of pneumococcal conjugate vaccines, In:. WHO Expert Committee on Biological Standardization. Fifty-fourth report. Geneva, World Health Organization, 2005 (WHO Technical Report Series, No. 927), Annex 2."},{"key":"77413","doi-asserted-by":"crossref","unstructured":"Andrade DC, Borges IC, Laitinen H. A fluorescent multiplexed bead-based immunoassay (FMIA) for quantitation of IgG against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis protein antigens. J Immunol Methods. 2014; 405:130-143.","DOI":"10.1016\/j.jim.2014.02.002"},{"key":"77414","doi-asserted-by":"crossref","unstructured":"Meek B, Ekstrom N, Kantso B. Multilaboratory comparison of pneumococcal multiplex immunoassays used in immunosurveillance of Streptococcus pneumoniae across Europe. mSphere. 2019; 4(6):e00455-e00519.","DOI":"10.1128\/mSphere.00455-19"},{"key":"77415","doi-asserted-by":"crossref","unstructured":"Theilacker C, Fletcher MA, Jodar L, Gessner BD. PCV13 vaccination of adults against pneumococcal disease: what we have learned from the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA). Microorganisms. 2022; 10(1):127.","DOI":"10.3390\/microorganisms10010127"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/11968\/78170","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11968\/78624","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11968\/78170","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:08:18Z","timestamp":1794046098000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/11968"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":33,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.286942","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,6]]}}}